XBiotech (XBIT) Update on Phase III Oncology Study in Europe Shows Data Irregularities Affect 72 Patients
Tweet Send to a Friend
XBiotech (NASDAQ: XBIT) announced findings related to enrollment in the study. The Company is reporting that data cleaning has revealed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE